Research and development of daily news yjunshi new crown neutralizing antibodies into Phase I clinical and completed the first drug administration

Novartis triple therapy Enerzair Breezhale treatment asthma phase IIIb clinical primary endpoint; BI Nidanib China approved for the treatment of scleronopathic-related interstitial lung disease; Guangshengtang anti-hepatitis b virus drug Ramifdin tablets passed the consistency evaluation; reached the clinical end of Phase 2 clinical end! Innovative monotherapy for lupus significantly improves skin symptoms..We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referenceJunshi Bio announced on the 7th that its recombinant all-human anti-SARS-CoV-2 monoclonal antibody injection, jointly developed with the Institute of Microbiology of the Chinese Academy of Sciences, was approved for phase I clinical trial and completed the first case of subject administration at Huashan Hospital affiliated with Fudan UniversityNovartis recently announced that the full results of the ArgON study on the evaluation of single-inhaler triple therapy Enerzair Breezhaler for the treatment of asthma IIIb have been published in Respiratory Medicine, Biogen recently announced the company's development of the mono-antitherapy BIIB059 treatment of patients with erythematosus (CLE) clinical dataThe results showed that BIIB059 significantly improved disease symptoms compared to the placebo groupBollinger Ingham today announced that his anti-pulmonary fibrosis treatment, Virgat(Name Ofev
, Generic Name: Nidanib SoftCapsules, has been approved for NMPA, becoming the first and currently the only drug for interstitial pulmonary disease associated with systemic sclerosison8, the State Drug Administration announced that it had recently approved the registration of the "Through the Catheter Aorta Valve System" of an innovative product produced by Edwards Lifesciences LLCOn the 8th of, the Mersha Dongtemovir injection/tablet was approved for clinical use in China for allogeneic hematopoietic stem cell transplantation (HSCT) sero-positive adult recipients of the cytomegalovirus (CMV) to prevent CMV reactivation and diseasetoday, Roche's clinical application for Tiragolumab Injection, a TIGIT monotoreactor, was accepted by CDE today, Y-mAbs Therapeutics announced that the company's biologics licensing application for GD2 antibody naxitamab has been accepted by the FDA and granted priority review status, and that the indications are patients with recurrent/refractive high-risk neuroblastomaThe FDA is expected to respond by November 308, Guangshengtang issued a notice that the company recently received the State Drug Administration approved the issuance of the "drug supplement application approval" on Ramif fixed tablets, the company Ramifdin tablets (He Ganding) through the quality of generic drugs and efficacy consistency evaluation.